ArticleCurrent oncology (Toronto, Ont.)2022

Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study.

Fiona Turkes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.